Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 532-536

  Delgado, Pilar ^a   Chacón, Pilar ^b   Penalba, Anna ^a   Pelegrí, Dolors ^b   Merino, Cristina ^a   Ribó, Marc ^b   Rubiera, Marta ^b   Álvarez Sabin, José ^b   Montaner, Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Reperfusion; Stroke; T PA, Thrombolysis

Indexed keywords

ALTEPLASE; ESTERASE; LP PLA2 ENZYME; UNCLASSIFIED DRUG;

AGED; ARTERY SURGERY; ARTICLE; BRAIN HEMORRHAGE; COLORIMETRY; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; STROKE; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORIMETRY; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRAVENOUS; MALE; MULTIVARIATE ANALYSIS; PHOSPHOLIPASES A2; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; SPAIN; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84855971736     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.016     Document Type: Article

References (20)

1. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3-4.5h after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
2. Rubiera M., Alvarez-Sabin J., Ribo M., et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005, 36:1452-1456.
3. Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed) 2009, 1:200-208.
4. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004, 91:1146-1151.
5. Marti-Fabregas J., Borrell M., Cocho D., et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 2005, 65:366-370.
6. Gorelick P.B. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 2008, 101:34F-40F.
7. Mannheim D., Herrmann J., Versari D., et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008, 39:1448-1455.
8. Elkind M.S., Tai W., Coates K., Paik M.C., Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073-2080.
9. Elkind M.S., Leon V., Moon Y.P., Paik M.C., Sacco R.L. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2009, 40:3233-3237.
10. Adams H.P., Bendixen B.H., Kappelle L.J., et al. III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
11. Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337:1521-1526.
12. Brott T.G., Haley E.C., Levy D.E., et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90min. Stroke 1992, 23:632-640.
13. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017-1025.
14. Pessin M.S., Del Zoppo G.J., Estol C.J. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990, 13:271-289.
15. Demchuk A.M., Burgin W.S., Christou I., et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001, 32:89-93.
16. Montaner J., Fernandez-Cadenas I., Molina C.A., et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006, 37:1205-1210.
17. Rubiera M., Ribo M., Delgado-Mederos R., et al. Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke 2006, 37:2301-2305.
18. Delgado Martínez P., Montaner Villalonga J., Chacón P., Purroy F., Ribó M., álvarez-Sabín J. Lipid profile in the hyperacute phase of ischemic stroke allows to decide cholesterol-lowering therapy. Med Clin (Barc) 2005, 124:295-297.
19. Jarvie J.L., Wang H., Kinney G.L., Snell-Bergeon J.K., Hokanson J.E., Eckel R.H. LpPLA2 activity and mass are distributed across subfractions of both LDL and HDL, and relate differently to CHD progression. Circulation 2010, 122:A14551.
20. Barth J.H., Jackson B.M., Farrin A.J., et al. Change in serum lipids after acute coronary syndromes: Secondary analysis of SPACE ROCKET Study data and a comparative literature review. Clin Chem 2010, 56:1592-1598. Hall AS and on behalf of the SPACE ROCKET Trial group.